Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative risk of glaucoma surgery in uveitis-associated versus primary open-angle glaucoma: a multicentre database study.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Incidence and Predictors of IOP-Lowering Treatment Following Detection of Referable Glaucoma in a Teleretinal Screening Program.

medRxiv : the preprint server for health sciences·2026
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

Ocular Biometric Determinants of Intraocular Pressure and Risk Factors for Ocular Hypertension: The Chinese American Eye Study.

Journal of glaucoma·2026
Same author

Increased Risk of Intraocular Pressure-Lowering Treatment in Patients with End-Stage Renal Disease Undergoing Hemodialysis.

Ophthalmology. Glaucoma·2026
Same author

Ultrasound elastography system for quantifying Age-Related biomechanical changes in ocular tissues.

Ultrasonics·2026
Same journal

Increased Risk for Ocular Surface Neoplasia in Recipients of Solid Organ Transplant.

American journal of ophthalmology·2026
Same journal

Aflibercept With vs Without Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Optical Coherence Tomography Angiographic changes from a randomized clinical trial.

American journal of ophthalmology·2026
Same journal

Posterior Segment Risk Factors for Penetrating Keratoplasty Failure.

American journal of ophthalmology·2026
Same journal

Rates, Timing, and Predictors of Retreatment Across Risk-Cohorts in Retinopathy of Prematurity: Intravitreal Bevacizumab Injection vs Laser.

American journal of ophthalmology·2026
Same journal

Second-Generation ELZA-sub400 Protocol: Individualized High-Fluence Cross-Linking for Ultra-Thin Keratoconus Corneas.

American journal of ophthalmology·2026
Same journal

Comment on: Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease.

American journal of ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

Risk-Stratified Monitoring of Open Angle Glaucoma Suspects Based on Diagnostic Conversion Risk.

Kristy Yoo1, Linda Wu2, Alanna James1

  • 1Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Keck School of Medicine at the University of Southern California, Los Angeles, California.

American Journal of Ophthalmology
|June 4, 2026
PubMed
Summary
This summary is machine-generated.

Annual conversion from open-angle glaucoma suspects (OAGS) to primary open-angle glaucoma (POAG) is under 6% after the first year. A risk-stratified approach can tailor follow-up frequency, improving efficiency and patient care.

Keywords:
Glaucoma Suspectglaucoma epidemiologyopen angle glaucomaprimary open angle glaucoma

Related Experiment Videos

Last Updated: Jun 6, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Public Health

Background:

  • Open-angle glaucoma suspects (OAGS) represent a significant patient population at risk of progressing to primary open-angle glaucoma (POAG).
  • Current follow-up protocols for OAGS are often standardized, potentially leading to inefficient resource allocation and suboptimal patient monitoring.
  • Understanding the annual conversion rates and identifying determinants of progression are crucial for developing personalized surveillance strategies.

Purpose of the Study:

  • To determine the annual rates of diagnostic conversion from OAGS to POAG in the United States.
  • To identify key factors influencing the conversion risk from OAGS to POAG.
  • To develop a pragmatic, risk-stratified framework for optimizing follow-up frequency based on individual conversion risk.

Main Methods:

  • A retrospective cohort study was conducted using a large de-identified claims database (Optum Clinformatics® Data Mart).
  • Patients newly diagnosed with OAGS between 2007 and 2021 were included, requiring specific enrollment periods and diagnostic criteria.
  • Cox proportional hazards modeling was employed to analyze factors associated with conversion to POAG, with secondary analyses stratifying by age and treatment status.

Main Results:

  • The overall annual conversion rate from OAGS to POAG was 6.1%, with 20.6% of patients converting during the study period.
  • Factors associated with increased conversion risk included older age, male sex, Black race, specific geographic locations, gonioscopy records, and OAGS treatment.
  • Annual conversion rates varied significantly, from 2.0% in low-risk patients to 16.7% in high-risk patients, informing tailored follow-up intervals.

Conclusions:

  • The annual conversion rate from OAGS to POAG is generally low (<6.0%) after the initial year post-diagnosis.
  • A risk-stratified surveillance strategy, informed by per-visit conversion probability, can enhance clinical efficiency.
  • Tailoring follow-up frequency can safely reduce visits for low-risk individuals while ensuring timely detection in higher-risk groups, optimizing resource allocation.